Pulmonary Metastases in Urogenital Cancers; Surgical Treatment and Outcomes

Kenan Can Ceylan
Doktor Suat Seren Gogus Hastalıkları ve Cerrahisi Eğitim ve Araştırma Hastanesi

Güntüğ Batihan (gbatihan@hotmail.com)
University of Health Sciences, Dr Suat Seren Chest Diseases and Surgery, Medical Practice and Research Center  https://orcid.org/0000-0001-5258-2856

Seyda Ors Kaya
Doktor Suat Seren Gogus Hastalıkları ve Cerrahisi Eğitim ve Araştırma Hastanesi

Research article

Keywords: Lung metastasis, Metastasectomy, Pulmonary resection, Urogenital tumors, VATS

DOI: https://doi.org/10.21203/rs.3.rs-105384/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background Metastasis is remaining one of the major problems in cancer treatment. Like many other malignancies, urogenital tumors originating from kidney, prostate, testes, and bladder tend to metastasize to the lungs.

The aim of this retrospective study is to evaluate the results of pulmonary metastasectomy in patients with primary urogenital tumors.

Methods This study was approved by the local ethical committee. This study retrospectively analyses the patients who underwent lung resections for metastases in our department between 2002 and 2018. 22 out of 126 patients referred for pulmonary metastasectomy to our department had metastases from urogenital tumors.

Demographic data and clinicopathological features were extracted from the medical records. Disease-free interval (DFI) was defined as the time between the first curative surgery and the detection of pulmonary metastasis.

Results Among 22 patients who underwent lung metastasectomy consisted of 17 males and five females. Their metastasis originated from renal cell carcinoma (RCC; n = 9), bladder tumor (n = 7), testis tumors (n = 4), and prostate cancer (n = 2). There was no intraoperative complication. Postoperative complications were seen in 2 patients.

Conclusions Although pulmonary metastases and its surgical management in various types of tumors is well known and documented, the data is limited to the role of the surgery for metastases of urogenital cancers on literature. Despite the limitations of this study, we aim to document our promising results of pulmonary metastasectomy in patients with primary urogenital tumors.

Trial registration This study was approved by the local ethical committee (Registration number: 49109414-604.02 ; Date: 11/06/2019).

Background

Metastasis remains one of the major problems in cancer treatment. Like many other malignancies, urogenital tumors originating from kidney, prostate, testes, and bladder tend to metastasize to the lungs [1, 2]. Unfortunately, the presence of metastases is usually associated with a poor prognosis. Although there is no consensus on this issue, metastasectomy may be the part of the treatment especially in cases in which the primary disease is under control [1–3]. In many cases sublobar non-anatomic resections sufficient to ensure complete excision and care should be taken to sparing the lung tissue during metastasectomy.

There is no prospective, randomized study in this issue therefore the information on long-term survival in patients surgically treated for urogenital cancers’ lung metastases is limited. Besides, studies in the
literature are usually focused on subtypes of urogenital cancers, and collective publications are extremely rare.

This retrospective study and literature review aim to evaluate the results of pulmonary metastasectomy in patients with primary urogenital tumors and make a contribution to the literature by clarifying the role of surgery in treatment.

**Methods**

This study was approved by the local ethical committee. We retrospectively analyzed 126 patients who underwent lung resections for metastases in our department between January 2002 and December 2018. The patients included in the study consisted of who had received curative treatment for one of the urogenital malignancies and were in routine follow-up. Ovarian and uterine malignancies were excluded. During the study period, synchronous metastases are also observed, but all these cases had disseminated disease, and lung resections (wedge resections) only performed for diagnostic purposes. Therefore, synchronous metastases are excluded. Inclusion and exclusion criteria for the study are shown in Table 1. Twenty-two patients who met the inclusion criteria were eligible for participation in the study.

Demographic data and clinicopathological features were extracted from the medical records. Disease-free interval (DFI) was defined as the time between the first curative surgery and the detection of pulmonary metastasis. Surgical procedures, metastasis localizations, histopathological results, perioperative and postoperative complications were noted. An electronic literature search of PubMed was performed by entering the combination of keywords (UROGENITAL CANCER) and (METASTASECTOMY) and (PULMONARY).

Statistical analysis was performed using SPSS 25.0 (SPSS Inc., Chicago, IL, USA). Categorical variables were analyzed using Chi-square tests. Continuous variables were analyzed using the Mann–Whitney U test. Survivals were estimated using the Kaplan-Meier method.

**Results**

Among 22 patients who underwent surgery consisted of 17 males and five females. Their metastasis originated from renal cell carcinoma (RCC; n = 9), bladder tumor (n = 7), testis tumors (n = 4), and prostate cancer (n = 2). Their mean age was 57.11 years (range, 21–75). The mean age of the patients with RCC and bladder tumor at the time of diagnosing metastasis was 57.6 and 59.33 years, respectively. The mean age of patients with testis tumors is 27 (Table 2).

The majority of patients had no symptoms, and their metastasis was detected incidentally in their routine follow-up. Two patients with centrally localized tumors were presented with severe cough and mild hemoptysis.
The site of metastasis was left lung in fifteen, right lung in six patients. One patient had bilateral lung metastases.

Wedge resection applied in seventeen cases with negative surgical margins. Lobectomy, instead of wedge resection, was applied in three patients because of the multiple metastases located in only one lobe. Due to the central localization of the metastasis and the presence of hemoptysis and destroyed lung, we had to applied pneumonectomy in two cases. These two patients were in good performance status and tolerated the pneumonectomy well. In 13 patients, the operation was started with VATS but was converted to thoracotomy because the metastatic nodules were not detected. Muscle-sparing lateral thoracotomy applied in seven patients. In patients operated on by VATS had shorter hospitalization and drainage time and better postoperative pain status than thoracotomy (Table 3).

Re-operation was needed, and wedge resection was applied in one case due to the recurrent lung metastasis one year after the first surgery.

No major complications occurred during surgery. Postoperative complications were observed in 2 patients in total. Postoperative hemorrhage was seen in one patient in the early postoperative period, and re-operation was applied.

Prolonged air leakage was observed in one patient and we managed this complication using the Heimlich valve system. In this patient, the chest tube was removed at the end of the first postoperative month. No major complication occurred in other patients on postoperative follow-up.

The median follow-up time was 50 months (range, 20 to 156 months). The 1-month survival was 100%, but the 2-years survival was 66.6% (for RCC), 57.1% (Bladder tumor), 50% (testis tumor) and 0% (prostate cancer) (Table 4).

**Discussion**

Although lung metastasis excision in various types of tumors is well known and documented, the data is limited to the role of the surgery for metastases of urogenital cancers on literature (Table 5).

Considering the renal cell carcinoma, it was reported that 5-years survival rates are between 21% and 60% after pulmonary metastasectomy [2–8]. It was also shown that metastasectomy would have an additional contribution to prognosis, especially in patients with few and small metastases and longer DFI [5–9]. Our study demonstrated 2-years survival rates 66.6% from renal cell carcinoma, after pulmonary metastasectomy.

In literature, studies have demonstrated 5-years survival rates between 15,9%-%33 from urothelial carcinoma, after pulmonary metastasectomy [9–14]. It was also shown that patients who had shown great response to chemotherapy and had no evidence of early or rapid progression elsewhere had been shown to benefit more from metastasectomy. In our experience, we had four cases of metastatic urothelial carcinoma with a 57.1% 2-years survival rate. Adjuvant therapy was not administered after the
pulmonary metastasectomy. There is limited data in the literature regarding the benefit of giving adjuvant treatment after complete metastasectomy in renal cell carcinoma. In these studies, there was no significant difference in survival in the group with and without systemic adjuvant therapy [15]. However, pulmonary metastasectomy combined with systemic targeted therapy and/or immunotherapy could be an optimal treatment approach in the future, but it needs to be supported by clinical trials.

The lung is the most common site of metastases in patients with testicular germ cell tumors. Studies demonstrated that resection of the pulmonary metastases has a positive effect on survival rates, especially patients with lesions limited to one site. In literature, 5-years survival rates were reported between 45%-65% after metastasectomy [16–22]. McGuire MS et al. have reviewed 105 patients with NSGCTs who undergone thoracotomy because of pulmonary metastasis and the viable non-teratomatous disease in the chest or retroperitoneum was described as a poor prognostic factor [18]. In another study, Pfannschmidt J et al. have reviewed 52 cases of NSGCT who undergone pulmonary metastasectomy, and 5-year survival was reported as 75.8%. The authors described incomplete resection and elevated tumor marker levels, AFP and/or hCG as poor prognostic factors [19]. In our study, we had 4 cases of testicular tumors which histological types were embryonal carcinoma. These patients underwent radical inguinal orchiectomy, retroperitoneal lymph node dissection, and adjuvant chemotherapy. However, because of metachronous pulmonary metastases, surgical resection was needed, and adjuvant chemotherapy was administered. The 2-years survival was detected as 50% after pulmonary metastasectomy.

Isolated solitary pulmonary metastases are extremely rare in prostate carcinomas. In prostate carcinoma, lung metastases usually present diffuse interstitial or multinodular patterns, and there is no clue about the survival benefit of pulmonary metastasectomy [23, 24]. Therefore, pulmonary metastasectomy should be performed only if the patient has solitary pulmonary metastasis resistant to hormone therapy or has severe respiratory symptoms refractory to conservative management. In our experience, we had only two patient of prostate carcinoma who underwent wedge resection. These two patients died in the first six postoperative month due to disease progression.

It is also important to choose the appropriate surgical method in patients with pulmonary metastases. Video-assisted thoracoscopic surgery (VATS) has well-documented benefits over open thoracotomy like less pain, less inflammatory response, shorter hospitalization and fast recovery after surgery [25–27]. The main concern regarding the use of VATS for metastasectomy is the risk of inability to performing complete resection. There isn’t any information in the literature to confirm these concerns. Several studies even reported no relation between VATS and open thoracotomy in recurrence in the ipsilateral lung [28, 29]. Therefore, VATS is routinely used in our clinic for pulmonary metastasectomy. Sometimes it would be difficult to localize metastatic nodules or ground-glass opacities (GGO) intraoperatively during the VATS procedure. Thankfully, various methods that make it possible to localize these kinds of lesions with the VATS technique have been described. The most commonly used methods for this purpose are methylene blue and hook wire marking [30]. We routinely use CT-guided methylene blue staining techniques in
patients with small nodules and GGOs (Fig. 1). Although the lesion is localized with almost complete accuracy by these marking methods, the confirmation should be performed with a frozen section.

In highly selected patients, resection of pulmonary metastases present minimal risk and prolong survival in urogenital tumors. Previous studies described the presence of prolonged DFI, unilateral metastases, surgically resectable tumors, and less than 3 radioimagistic detectable metastases, as a positive predictive factor. With this study, we aim to evaluate the results of pulmonary metastasectomy in patients with primary urogenital tumors in our clinic.

**Conclusion**

Nowadays, with the increasing use of minimally invasive methods, operation and hospitalization times have been shortened, and second, third, or even fourth operations in the same patient have become more possible and easier for both patient and surgeon. Although there is no consensus in the management of these patients in the literature, we suggest pulmonary metastasectomy in urogenital cancers especially for patients with good respiratory conditions. We also recommend the usage of video-thoracoscopic surgery instead of thoracotomy. Small nodules and ground-glass opacities can cause problems for VATS, but as we have mentioned, this problem can be overcome by marking techniques.

**List Of Abbreviations**

CT: Computed tomography

DFI: Disease free interval

GGO: Ground glass opacity

NSGCT: Non-seminomatous germ cell tumor

RCC: Renal cell carcinoma

VATS: Video-assisted thoracic surgery

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the ethical committee of The University of Health Sciences Dr Suat Seren Chest Diseases and Chest Surgery Research and Training Center (Registration number: 49109414-604.02 ; Date: 11/06/2019).

**Consent for publication**

Not applicable.
Availability of data and materials

Data are not publicly available. Data are however available from the authors upon reasonable request and with permission.

Competing interests

The authors declare that they have no competing interests.

Funding

The authors received no specific funding/support for this study.

Authors' contributions

KCC and SOK analyzed and interpreted the patient data regarding the pulmonary metastasis. GB performed the statistical analyses and was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

References

1. Heidenreich A, Wilop S, Pinkawa M, Porres D, Pfister D. Surgical resection of urological tumor metastases following medical treatment. Dtsch Arztebl Int. 2012;109(39):631–7.
2. Radulescu IM, Popescu R, Cirstoiu MM, Cordos I, Mischianu D, Cirstoiu CF. Surgical treatment for pulmonary metastases in urogenital cancers. J Med Life. 2014;7(3):358–62.
3. Masoum SHF, Kerigh BF, Goreifi A. Pulmonary and Chest Wall Metastasectomy in Urogenital Tumors: A Single Center Experience and Review of Literature. Nephrourol Mon. 2014 May;6(3):e17258.
4. Kim JJ, Park JK, Wang YP. Surgical resection of pulmonary metastasis from renal cell carcinoma. Korean J Thorac Cardiovasc Surg. 2011;44(2):159–64.
5. Kawashima A, Nakayama M, Oka D, Sato M, Hatano K, Mukai M, et al. Pulmonary metastasectomy in patients with renal cell carcinoma: a single-institution experience. Int J Clin Oncol. 2011;16:660–5.
6. Friedel G, Hürtgen M, Penzenstadler M, Kyriss T, Toomes H. Resection of pulmonary metastases from renal cell carcinoma. Anticancer Res. 1999;19:1593–6.
7. Cerfolio RJ, Allen MS, Deschamps C, Daly RC, Wallrichs SL, Trastek VF, et al. Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg. 1994;57(2):339–44.
8. Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol. 2005;48(1):77–81.
9. Cowles RS, Johnson DE, McMurtrey MJ. Long-term results following thoracotomy for metastatic bladder cancer. Urology. 1982;20(4):390–2.

10. Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol. 2004;171(1):145–8.

11. Matsuguma H, Yoshino I, Ito H, Goya T, Matsui Y, Nakajima J, et al. Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma? Ann Thorac Surg. 2011;92:449–53.

12. Han WS, Kim K, Park JS. Result of surgical resection for pulmonary metastasis from urothelial carcinoma. Korean J Thorac Cardiovasc Surg. 2012;45:242–5.

13. Kanzaki R, Higashiyama M, Fujiwara A, Tokunaga T, Maeda J, Okami J, et al. Outcome of surgical resection of pulmonary metastasis from urinary tract transitional cell carcinoma. Interact Cardiovasc Thorac Surg. 2010;11:60–4.

14. Kim T, Ahn JH, You D, Jeong IG, Hong B, Hong JH, et al. Pulmonary Metastasectomy Could Prolong Overall Survival in Select Cases of Metastatic Urinary Tract Cancer. Clin Genitourin Cancer. 2015;13(4):1–7.

15. Husillos Alonso A, Carbonero García M, González Enguita C. Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma? World J Nephrol. 2015;4(2):254–62.

16. Liu D, Abolhoda A, Burt ME, Martini N, Bains MS, Downey RJ, et al. Pulmonary metastasectomy for testicular germ cell tumors: A 28-year experience. The Annals of Thoracic Surgery. 1998;66(5):1709–14.

17. Einhorn LH, Williams SD, Mandelbaum I, Donohue JP. Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer. 1981;48(4):904–8. Thorac Cardiov Surg 2006; 54: 484–488.

18. McGuire MS, Rabbani F, Mohseni H, Bains M, Motzer R, Sheinfeld J. The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours. BJU Int. 2003;91:469–73.

19. Pfannschmidt J, Zabeck H, Muley T, Dienemann H, Hoffmann H. Pulmonary Metastasectomy Following Chemotherapy in Patients with Testicular Tumors: Experience in 52 Patients. Thorac Cardiov Surg. 2006;54:484–8.

20. Anyanwu E, Krysa S, Buelzebruck H, Vogt-Moykopf I. Pulmonary metastasectomy as secondary treatment for testicular tumors. Ann Thorac Surg. 1994;57:1222–8.

21. Gels ME, Hoekstra HJ, Sleijfer DT, Nijboer AP, Molenaar WM, Ebels T, et al. Thoracotomy for postchemotherapy resection of pulmonary residual tumor mass in patients with nonseminomatous testicular germ cell tumors: aggressive surgical resection is justified. Chest. 1997;112:967–73.

22. Horvath LG, McCaughan BC, StockleM, Boyer MJ. Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours. Intern Med J.
23. Goto T, Maeshima A, Oyamada Y, Kato R. Solitary pulmonary metastasis from prostate sarcomatoid cancer. World J Surg Oncol. 2010;8:101.

24. Wallis CJ, English JC, Goldenberg SL. The role of resection of pulmonary metastases from prostate cancer: a case report and literature review. Can Urol Assoc J. 2011;5(6):E104–8.

25. Villamizar N, Darrabie M, Burfriend W, Petersen RP, Onaitis MW, Toloza E, et al. Thoracoscopic lobectomy is associated with lower morbidity compared with thoracotomy. J Thorac Cardiovasc Surg. 2009;138:419–25.

26. McKenna R, Houck W, Fuller C. Video-assisted thoracic surgery lobectomy. Ann Thorac Surg. 2006;81:421–6.

27. Taioli E, Lee D, Lesser M, Flores R. Long-term survival in video-assisted thoracoscopic lobectomy vs open lobectomy in lung-cancer patients: a meta-analysis. Eur J Cardiothorac Surg. 2013;44:591–7.

28. Carballo M, Maish MS, Jaroszewski DE, Yetasook A, Bauer K, Cameron RB, et al. Video-assisted thoracic surgery (VATS) for resection of metastatic adenocarcinoma as an acceptable alternative. Surg Endosc. 2009;23(9):1947–54.

29. Hou Z, Zhang H, Gui L, Wang W, Zhao S. Video-assisted thoracoscopic surgery versus open resection of lung metastases from colorectal cancer. Int J Clin Exp Med. 2015;8(8):13571–7.

30. Kleedehn M, Kim DH, Lee FT, Lubner MG, Robbins JB, Ziemlewicz TJ, et al. Preoperative pulmonary nodule localization: a comparison of methylene blue and hookwire techniques. AJR Am J Roentgenol. 2016;207(6):1334–9.

Tables

Table I. Inclusion and exclusion criteria

| Inclusion                                                                 | Exclusion                        |
|--------------------------------------------------------------------------|----------------------------------|
| Urogenital malignancies (Renal cell carcinoma, urothelial carcinoma, testicular tumor, prostate carcinoma) | Ovarian and uterine malignancies |
| Patients who underwent pulmonary resection with malignant negative margin for pulmonary metastasis | Uncontrolled primary disease |
| Metachronous metastasis                                                  | Mediastinal lymph node involvement |
|                                                                          | Extrapulmonary metastasis         |
|                                                                          | Synchronous metastasis            |

Table II. Characteristics of patients.
| Primary Disease | Number of Patients | Mean Age | Operation |
|-----------------|--------------------|----------|-----------|
| RCC*            | 9                  | 58.5     | 1 pneumonectomy, 1 lobectomy, 7 wedge resections |
| Bladder TCC*    | 7                  | 65.1     | 2 lobectomy, 5 wedge resections |
| Testis ca       | 4                  | 33.6     | 1 pneumonectomy, 3 wedge resection |
| Prostate ca     | 2                  | 71.5     | 2 wedge resection |
| Overall         | 22                 | 56.7     | 2 pneumonectomy, 3 lobectomy, 17 wedge resections |

*RCC: Renal cell carcinoma, TCC: transitional cell carcinoma (urothelial carcinoma)

Table III. Postoperative results of the VATS and thoracotomy

|                                | VATS (n=11) | Thoracotomy (n=11) | P value |
|--------------------------------|-------------|--------------------|---------|
| Mean drainage time (day)       | 3.00        | 4.67               | 0.06    |
| Mean hospital stay (day)       | 3.80        | 5.67               | 0.029   |
| Postoperative complication (%) | 4.5         | 4.5                | 0.649   |
| VAS score*                     |             |                    |         |
| · Day 1                        | 4.00        | 4.33               | 0.438   |
| · Day 2                        | 2.60        | 3.78               | 0.029   |
| · Day 3                        | 2.40        | 3.44               | 0.083   |

* visual analog scale: Scoring system that used for measuring the acute and chronic pain.

Table IV. Disease free intervals and survivals of the patients.

| Primary disease | Number of Patients | DFI* | 1 month | 6 months | 2 years |
|-----------------|--------------------|------|---------|----------|---------|
| RCC*            | 9                  | 28.8 | 100.0%  | 88.8%    | 66.6%   |
| Bladder TCC*    | 7                  | 15   | 100.0%  | 100.0%   | 57.1%   |
| Testis ca       | 4                  | 18   | 100.0%  | 100.0%   | 50%     |
| Prostate ca     | 2                  | 12   | 100.0%  | 100.0%   | 0%      |

*RCC: Renal cell carcinoma, TCC: transitional cell carcinoma (urothelial carcinoma), DFI: Disease free interval(month).
Table V. Literature review.

| Authors                | Study year | Number of Patients | Pathology of primary disease | Median survival (months) | Ref. |
|------------------------|------------|--------------------|------------------------------|--------------------------|------|
| Cerfolio RJ et al.     | 1994       | 96                 | RCC a                        | 36                       | 7    |
| Friedel G et al.       | 1999       | 77                 | RCC                          | 37                       | 6    |
| Hofmann HS et al.      | 2005       | 64                 | RCC                          | 39.2                     | 8    |
| Kim JJ et al.          | 2011       | 15                 | RCC                          | 34.9                     | 4    |
| Kawashima A et al.     | 2011       | 25                 | RCC                          | 33.9                     | 5    |
| Cowles RS et al.       | 1982       | 6                  | UC b                         | 60                       | 9    |
| Siefker-Radtke AO et al.| 2004     | 31                 | UC                           | 23                       | 10   |
| Kanzaki R et al.       | 2010       | 18                 | UC                           | 52                       | 13   |
| Matsuguma H et al.     | 2011       | 32                 | UC                           | 60                       | 11   |
| Han WS et al.          | 2012       | 16                 | UC                           | 60                       | 12   |
| Kim T et al.           | 2015       | 30                 | UC                           | 30                       | 14   |
| McGuire MS et al.      | 2003       | 105                | NSGCTs                       | *                        | 18   |
| Pfannschmidt J et al.  | 2006       | 52                 | NSGCTs                       | 75.8 % (5-year survival) | 19   |
| Goto T et al.          | 2010       | 1                  | Prostate ca                  | **                       | 23   |
| Wallis CJ et al.       | 2011       | 1                  | Prostate ca                  | **                       | 24   |
| Radulescu IM et al.    | 2014       | 26                 | Urologic cancers: 8          | ***                      | 2    |
|                        |            |                    | Genital cancers: 16          |                          |      |
| Masoum SHF et al.      | 2014       |                    |                              |                          | 3    |

a Renal cell carcinoma

b Urothelial carcinoma
c Non-seminomatous germ cell tumor of testis

* There is no overall survival data in this study but viable non-teratomatous disease in the chest
or retroperitoneum was described as a negative predictive factor of disease-free survival.

** The number of cases undergoing pulmonary metastasectomy for prostate cancer is very limited in the literature therefore, we reviewed 2 well written case report.

*** 6 months survival was reported as 100% for urologic cancers and 94.44% for genital cancers.